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Insulin-induced gene 2 (INSIG2) and its homolog INSIG1
encode closely related endoplasmic reticulumproteins that reg-
ulate the proteolytic activation of sterol regulatory element-
binding proteins, transcription factors that activate the synthe-
sis of cholesterol and fatty acids in animal cells. Several studies
have been carried out to identify INSIG2 genetic variants asso-
ciated with metabolic diseases. However, few data have been
published regarding the regulation of INSIG2 gene expression.
Two Insig2 transcripts have been described in rodents through
the use of different promoters that produce different noncoding
first exons that splice into a common second exon. Herein we
report the cloning and characterization of the human INSIG2
promoter and the detection of an INSIG2-specific transcript
homologous to the Insig2bmouse variant in human liver. Dele-
tion analyses on 3 kb of 5-flanking DNA of the human INSIG2
gene revealed the functional importance of a 350-bp region
upstream of the transcription start site.Mutated analyses, chro-
matin immunoprecipitation assays, and RNA interference anal-
yses unveiled the significance of an Ets-consensus motif in the
proximal region and the interaction of the Ets family member
SAP1a (serum response factor (SRF) accessory protein-1a) with
this region of the human INSIG2 promoter.Moreover, our find-
ings suggest that insulin activated the human INSIG2 promoter
in a process mediated by phosphorylated SAP1a. Overall, these
results map the functional elements in the human INSIG2 pro-
moter sequence and suggest an unexpected regulation of
INSIG2 gene expression in human liver.
Metabolic syndrome, which is characterized by visceral obe-
sity, dyslipidemia, hyperglycemia, and hypertension, has
become one of the most significant public health challenges
worldwide. Although the association of several of these risk
factors has been known for more than 80 years, their clustering
received scant attention until 1988, when Reaven (1) described
syndrome X, which was subsequently renamed metabolic syn-
drome. Reaven (1) proposed that insulin resistance is the initial
cause that triggers the other symptoms of syndrome X,
although Lemieux et al. (2) suggested that visceral obesity and
the hypertriglyceridemic waist phenotype were central compo-
nents. The cause of this syndrome therefore remains unclear.
SREBP1c (sterol regulatory element-binding protein 1c) is an
essential transcription factor for the genomic actions of insulin
on both carbohydrate and lipidmetabolism (3). Changes in this
transcription factor activity might therefore be the key to link-
ing insulin resistance with themetabolic disorders proposed by
Lemieux et al. (2) at themolecular level. Indeed, type 2 diabetes
and obesity, two common insulin-resistant states, are charac-
terized by a decrease in SREBP1cmRNA levels in adipose tissue
(4). In contrast, an elevated expression of SREBP1c has been
found in the liver of obese (ob/ob) mice, in insulin receptor
substrate-2-deficient mice and also in a transgenic mouse
model of lipodystrophy (5, 6).
After their synthesis on membranes of the endoplasmic
reticulum (ER)4 in an inactive form, SREBPsmove in vesicles to
the Golgi complex, where they are processed sequentially
by two proteases (7). These cleavages release a cytosolic tran-
scription factor domain that enters the nucleus and activates
genes that produce more than a score of enzymes required for
the synthesis of cholesterol and unsaturated fatty acids as well
as phospholipids and triglycerides (8). In the ER, SREBPs asso-
ciate with SREBP cleavage-activating protein, which functions
as a sensor of cholesterol levels and, in turn, interacts with
another class of ER-embedded proteins, the so-called insulin-
inducible gene (INSIG) proteins.When cellular cholesterol lev-
els are high, INSIG proteins bind and trap SREBP cleavage-
activating protein, thereby retaining it in the ER and preventing
it from escorting SREBPs from the ER to the site of proteolytic
activation in the Golgi complex. Thus, the ER-to-Golgi migra-
tion of SREBPs is crucially dependent on INSIG proteins.
Two INSIG isoforms, designated INSIG1 and INSIG2, are
known (9). The two human INSIG proteins are 59% identical
and both bind SREBP cleavage-activating protein in a sterol-de-
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pendent fashion. Themajor differences between these two pro-
teins relate to the regulation of their expression. Thus, INSIG1
is itself an obligatory SREBP target gene, whereas INSIG2 is
expressed at a low but constitutive level, at least in cultured
cells, and is not regulated by SREBPs (10).
Yabe et al. (9) reported the discovery of a liver-specific tran-
script of Insig2 in rodents, designated Insig2a, which differs
from the ubiquitous transcript, called Insig2b, in the noncoding
first exons that splice into a common second exon through the
use of different promoters. Although both transcripts encode
identical proteins, they differ in terms of regulation patterns.
The Insig2a transcript is down-regulated by insulin, and the
resulting drop in Insig2a allows SREBP1c, the predominant iso-
form in the liver, to be processed independently of hepatic cho-
lesterol levels. However, the direct role of insulin on suppres-
sion of the Insig2a promoter has not been demonstrated.
Different loci linked to body mass index and/or obesity in
mice (11) and humans (12), including the locus where the
INSIG2 gene is located, have been detected by genome-wide
linkage analyses. Moreover, using a comprehensive single
nucleotide polymorphism map constructed over 62 common
strains of mice, Insig2 was identified as a strong candidate sus-
ceptibility gene for total plasma cholesterol levels, free fatty
acids, aortic lesions, and fat pad mass (13).
Although no data are yet available on human polymorphic
variation in components of the INSIG family, Herbert et al. (14)
identified a genetic variant associated with obesity in the
genomic region where INSIG2 is located using a dense whole
genome scan of DNA samples from Framingham Heart Study
participants.
In light of the above findings, our objective was to clone and
characterize the functional elements in the human INSIG2 pro-
moter. Our results demonstrate for the first time that members
of the Ets family of transcription factors are involved in the
regulation of human INSIG2 expression and therefore of
SREBP processing.
EXPERIMENTAL PROCEDURES
Plasmid Constructs—A PCR fragment of the 5 upstream
region of human INSIG2 gene was cloned into the pGEM-T
easy vector (Promega). INSIG2-luc vector was obtained by sub-
cloning into the SacI restriction site of pGL3-basic vector. The
2912, 1887, 1422, 859, 347, and 152/11 luc plas-
mids were obtained by restriction digestion from INSIG2-luc.
Mutagenesis was performed using the QuickChange site-di-
rectedmutagenesis kit (Stratagene), using INSIG2-luc as a tem-
plate. All constructs were confirmed by DNA sequencing. Vec-
tor pcDNA3-ELK1 was a gift from Dr. Robert A. Hipskind
(Hannover Medical School, Germany). Vectors pCAGGS,
pCA-SAP1a, and pCA-SAP1a DBD were obtained from Dr.
Hiroshi Kubota (Institute for FrontierMedical Sciences, Kyoto,
Japan). pcDNA-SAP1a was obtained by subcloning from pCA-
SAP1a. Vector pcDNA-E2F was provided by Dr. Yoshikuni
Nagamine (HowardHughesMedical Institute, DukeUniversity
Medical Center). Vector pcDNA-NRF2 was obtained from Dr.
Jose Blesa (Instituto de Biomedicina de Valencia, Spain). Ras
expression vector pCEFL-K5-KRasV12 was a gift from Dr. Jose´
María Rojas (Centro Nacional de Microbiología, Spain).
Cell Culture and Luciferase Assay—Human embryonic kid-
ney 293T (HEK293T) cells were maintained in Dulbecco’s
modified Eagle’s medium containing 25 mmol/liter glucose,
100 units/ml penicillin, and 100 g/ml streptomycin supple-
mented with 10% fetal bovine serum. Cells were seeded in
6-well culture dishes and transiently transfected using Lipo-
fectamine 2000 (Invitrogen) according to the manufacturer’s
protocol. Each well received 3.8 g of INSIG2 reporter plas-
mids and 200 ng of a Renilla luciferase construct (pRL-TK) as
internal control. The human liver carcinoma HepG2 cell line
was cultured in the same medium as HEK293T, but transfec-
tion assays were performed in 24-well culture dishes using 850
FIGURE 1. Alternative sequences at the 5-end of INSIG2 mRNA from
mouse or human liver. A, the nucleotide sequences of the first exons of
mouse Insig2a and -2b were aligned with human sequence on the basis of
coding exon 2 to predict the putative exons in the human gene. B, total RNA
from the indicated tissues or cell lines was analyzed by RT-PCR analysis as
described under “Experimental Procedures.” Specific primers were used to
determine the presence of each variant in different organisms and cell types.
Variant Insig2a is only present in mouse and rat liver and is not detected in
human liver or cell lines.MW, molecular weight.
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ng of INSIG2 reporter plasmids and 50 ng of the pRL-TK vec-
tor. In ELK1 and SAP1a overexpression experiments, 50 ng of
each vector was added together with 0, 10, 25, or 50 ng of K-Ras
expression vector. Luciferase activities were measured 24 or
48 h after transfection in aWallac 1420 VICTOR luminometer
according to the technical manual for the Dual-Luciferase
reporter assay system (Promega).
Rat hepatocytes were isolated from fed rats by the collagen-
ase method (15) and seeded in Williams E medium supple-
mented with 25 mM glucose, 100 nM insulin, 1 M dexametha-
sone, 5% fetal bovine serum, and antibiotics. Transfection
assays were performed in 6-well culture dishes using Lipo-
fectamine with 3.8 g of INSIG2 reporter plasmids and 200 ng
of the pRL-TK control vector. For metabolic studies, hepato-
cytes were incubated for 6 h in Dulbecco’s modified Eagle’s
medium, 1 g/liter (low) glucose medium 24 h after transfection
and then cultured in either low or high (4.5 g/liter) glucose
medium for an additional 24 h, either unstimulated or stimu-
lated with 100 nM insulin. Transactivation activities were mea-
sured as above.
Human hepatocytes in a monolayer were obtained from 3H
Biomedical (Uppsala, Sweden) and maintained in Williams E
medium supplemented with 25 mM glucose, 100 nM insulin, 1
M dexamethasone, 5% fetal bovine serum, and antibiotics.
Where indicated, the medium was
changed to culture medium supple-
mented with 400 M palmitic acid
dissolved in methanol or vehicle
alone for 24 h, and the cells were
incubated with or without 100 nM
insulin for a further 24 h.
Total RNA Preparation and
Quantitative RT-PCR—Total cellu-
lar RNAwas isolated frommouse or
rat liver, human hepatocytes, and
HEK293T or HepG2 cells using
TRIzol reagent (Invitrogen), follow-
ing the manufacturer’s instructions.
Human RNA was purchased from
Ambion (Applied Biosystems). To-
tal RNA (1 g) was reverse tran-
scribed into cDNA using Expand
reverse transcriptase (Roche Ap-
plied Science) and random hexamer
primers (Roche Applied Science).
cDNA was used as a template for
conventional PCR using specific
primers of INSIG2 isoforms for
each species (sequence available
upon request).
In siRNA experiments, HepG2
cells were transfected with 200 nM
human synthetic predesigned ELK1
short interfering RNA (siRNA) (ID
number 42834), SAP1a (ID number
3286), or silencer negative control
siRNA (Ambion). After incubation
for 48 h, cells were used for RNA
preparation and subsequent real-time quantitative PCR analy-
sis of knockdown.ELK1, SAP1a, and INSIG2mRNAexpression
levels were quantified using the ABI 7500 fast instrument and
Taqman technology (Assays-on-demand gene expression
product, Applied Biosystems). INSIG2b and SREBP1c mRNA
levels were monitored by SYBR Green using primers designed
specifically for these isoforms. All real-time quantitative PCRs
were performed in triplicate. Relative changes were calculated,
employing the second derivative comparative Ctmethod using
GAPDH as the internal reference gene.
Protein analysis was carried out byWestern blot as described
previously (16), using antibodies against ELK1 (sc-355) or
SAP1a (sc-13030) (Santa Cruz Biotechnology, Inc., Santa Cruz,
CA).
Electrophoretic Mobility Shift Assays—Double-stranded
DNA oligonucleotides end-labeled with [-32P]dATP were
used to perform electrophoretic mobility shift assays as
described previously (15). Binding reactions were carried out
for 20 min at room temperature using in vitro translated
human ELK1, SAP1a, NRF2, or E2F proteins, prepared with
the TNT T7-coupled reticulocyte lysate system (Promega), 9
fmol of probe, and 2 g of dI/dC. In supershift assays, spe-
cific antibodies (Santa Cruz Biotechnology, Inc.) were added
for 1 h on ice prior to the addition of probes. For competition
FIGURE 2. Characterization of the human INSIG2 gene proximal promoter region. The sequences in the
INSIG2promoter shownon the leftwere inserted into themultiple cloning regionsof thepGL3-basic vector and
transfected intoHEK293T (A) or HepG2 (B) cells. The results represent relative firefly/Renilla luciferase activities,
considering the 347/11 construct as 100% activation. Values are the mean  S.E. from four separate
experiments.
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experiments, a 25-fold excess of unlabeled oligonucleotide
was added to the reaction mixture. DNA-protein complexes
were resolved on a 6% (w/v) nondenaturing polyacrylamide
gel in 0.5 TBE buffer (1 TBE is 90 mM Tris, 90 mM boric
acid, and 1 mM EDTA).
Chromatin Immunoprecipitation (ChIP) Assay—ChIP assays
were performed using isolated nuclei from formaldehyde-
cross-linked HEK293T and HepG2 cells. DNA was sheared by
sonication, and the precleared chromatin was incubated with 2
g of the corresponding antibodies against ELK1 (sc-355),
SAP1a (sc-1426), SRF (sc-335), andRNApolymerase II (sc-899)
(Santa Cruz Biotechnology, Inc.). Samples were immunopre-
cipitated with protein A/G-Sepharose preblocked with bovine
serum albumin, tRNA, and sonicated -DNA. After RNase and
proteinase K treatment, and reverse cross-linking, DNA was
purified using QIAQUICK columns (Qiagen). The amount of
DNA in each chromatin immunoprecipitate was quantified by
real-time PCR on a 7500 Fast System (Applied) using SYBR
Green PCR reagent. A standard curve was established for each
amplicon by 10-fold serial dilutions of the input sample. Anal-
ysis of the c-fos promoter was used as a positive control for
ELK1 and SRF proteins. The PCR
primers used to detect target
sequences were as follows: INSIG2
(promoter), 5-CTCCAGTTTCC-
CGCAGACC-3 and 5-TCCGGT-
TCCTGCTGTCAATAA-3; c-fos
(promoter), 5-GCGAGCAGTTC-
CCGTCAAT-3 and 5-GAAAGG-
CCGTGGAAACCTG-3, GAPDH
(coding region), 5-AGCCACATC-
GCTCAGACACC-3 and 5-ACC-
CGTTGACTCCGACCTT-3. Each
ChIP assay was performed at least
twice to ensure reproducibility.
Statistical Analysis—Statistical sig-
nificance was estimated using Stu-
dent’s two-tailed t test for unpaired
observations. A p value of less than
0.05 was considered to be significant.
RESULTS
INSIG2a Transcript Is Not
Detected in Human Liver—A com-
parative analysis of human and
murine genomic sequences showed a
high degree of identity and similar
organization in terms of nucleo-
tide sequence between rodents
and humans in both the 1a and 1b
exons (Fig. 1A). This high se-
quence homology allowed us to
design primers to assess INSIG2a
and -2b expression in human, rat,
and mouse liver by RT-PCR anal-
ysis. Both mRNA variants were
detected in mouse and rat liver,
thereby confirming previous stud-
ies. However, INSIG2b was the only form of INSIG2 detected
in human liver (Fig. 1B). To confirm this result, we analyzed
the expression of INSIG2 variants in HEK293T and HepG2
cells. No trace of the INSIG2a transcript was found in any of
the two human cell lines analyzed, as predicted by in silico
analysis.
Functional Promoter Analysis of the 5-Flanking Region of the
Human INSIG2 Gene—Because the 2a transcript is not
expressed in the human liver, we analyzed the region upstream
of exon 1b to determine the cis elements responsible for trans-
activation of the INSIG2 gene. Serial 5 truncationsof thehuman
INSIG2 promoter were made upstream of the luciferase reporter
gene, and these constructs were transfected into HEK293T (Fig.
2A) orHepG2 cells (Fig. 2B). Analysis of these reporter constructs
revealed that a 350-bp region upstream of the transcription start
site was sufficient to retain full promoter activity. Moreover, the
first 150 bp still retain 40% of the promoter activity in both cell
lines, suggesting that this fragment contains a basal promoter
region critical for human INSIG2 gene expression.
After aligning the genomic sequences from mice and rats
with the corresponding identified proximal promoter region of
FIGURE3. Identificationof conservedputativebindingsites found in thehuman INSIG2promoter.The INSIG2
promoter sequences from humans, mice, and rats are aligned, including the exon 1 situation (shaded sequence).
Several highly conserved transcription factor binding siteswere identified. The putative binding sites are shown in
the figure and underlined on the sequences.
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human INSIG2, we identified several highly putative conserved
binding sites using a theoretical transcription factor binding
site search (TRANSFAC data base; Fig. 3). The contribution of
individual binding sites within the human INSIG2 proximal
promoter was defined by site-directed mutagenesis of the pro-
moter. Upon transient transfection into HEK293T cells, a dra-
matic drop in the reporter activity was observed when the Ets
elements were muted. Moreover, the Ets-a site mutation was
found to have the greatest effect (Fig. 4A). We repeated the
experiments with the 152/11 construct. In this context,
we only observed changes when the two Ets sites were
mutated, with a luciferase activity similar to that of the
pGL3-basic vector (Fig. 4B), indicating that the environment
has a key role in dictating the functional specificity of Ets
sites. Similar results were obtained upon transfection into
HepG2 cells (data not shown).
TRANSFAC analysis recognized ELK1, SAP1a, and NRF2
transcription factors as the putative binding proteins associ-
ated with the Ets elements. To determine whether these pro-
teins can indeed bind to the Ets-bindingmotifs of the INSIG2
promoter, we performed electrophoretic mobility shift
assays using different probes covering Ets elements (Fig. 5A)
in the presence of these in vitro translated human recombi-
nant proteins. As shown in Fig. 5B, bands representing spe-
cific protein-DNA interactions were only observed using
ELK1 and SAP1a proteins at the Ets-a (probe 1) binding site.
The complex was abolished in the presence of unlabeled
oligonucleotides and partially supershifted with specific
monoclonal antibodies. Moreover, no interactions were
observed when this binding site was mutated. E2F recombi-
nant protein was not able to bind to its putative element.
These results demonstrate that at least one Ets element
essential for basal human INSIG2 promoter activity binds
ELK1 and SAP1a transcription factors in vitro.
Association of ELK1 and SAP1a proteins to the INSIG2 pro-
moter was also demonstrated using the standard ChIP assay
followed by real-time PCR (Fig. 5C). After immunoprecipita-
tion, ELK1 and SAP1a were present in the human INSIG2 pro-
moter on genomic DNA extracted from growing HEK293T,
whereas only SAP1a was able to enrich the INSIG2 promoter
sequence from HepG2 chromatin. ELK1 and SAP1a usually
form a ternary nucleoprotein complex with the SRF, although
this does not bind to the human INSIG2 promoter in vivo. As a
positive control, we analyzed the c-fos promoter, a classic gene
controlled by the Ets factors associated with SRF. No enrich-
ment was seen using primers amplifying the GAPDH coding
region or nonspecific IgG antibody. In order to verify the results
obtained, the same samples employed for the ChIP assay were
used for the RNApol-ChIP assay, as described previously (17).
The -RNA polymerase antibody precipitated mainly coding
chromatin fragments.
Phosphorylated SAP1a Induces INSIG2 Promoter Activity—The
above results indicated that ELK1 and SAP1a may be critical
factors for the INSIG2 gene regulation. We investigated the
effect on INSIG2 promoter activity of knocking downELK1 and
SAP1a into the HepG2 cell line to determine their specific role.
A significant knockdownof either ELK1or SAP1awas observed
with siRNA targeting ELK1 (40%) or SAP1a (80%) but not with
the unrelated siRNAused as control (Fig. 6A).Moreover, SAP1a
interference also reduced the ELK1mRNA levels (50%). Western
blot analysis verified that ELK1 and SAP1a levels remained low in
ELK1 and SAP1a knockdown, respectively (Fig. 6C). We have
observed unchanged ELK1 protein levels after knocking down
SAP1a. Thus, the identification of the ELK gene as a potential
SAP1a target could be a false positive. Under these conditions, a
significant reduction in INSIG2 expression was only observed
when SAP1a siRNA was used. As a result, an increase in the
expression of SREBP1was also observed (Fig. 6B). These observa-
tions provide supporting evidence that SAP1a may be one of the
transactivators of the human INSIG2 promoter.
To assess the transcriptional activity of SAP1a on the human
INSIG2 promoter, a construct containing the minimal human
INSIG2 promoter region linked to a luciferase reporter plasmid
was analyzed inHepG2 cells cotransfectedwith SAP1a or ELK1
expression vectors or a dominant negative form that express
only the binding domain of SAP1a. Because the ability of SAP1a
to mediate transcriptional activation is dependent on its phos-
phorylation state, which in turn is regulated by ERKs (18), the
experiments were performed in the presence of a constitu-
FIGURE 4. Ets binding sites are critical for INSIG2promoter activity.Muta-
tionof diversepredictedbinding sites in theproximal promoterwas analyzed
by luciferase assays. Activities of themutated constructs on347/11 luc (A)
and 152/11 luc (B) transfected in HEK293T cells are shown. The results
represent relative firefly/Renilla luciferase activities considering thewild type
347/11 luc construct as 100% activation. Values are themean S.E. from
four separate experiments.
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tively active form of K-Ras, which
activates endogenous ERKs (19).
As shown in Fig. 7A, phosphoryla-
ted SAP1a activated INSIG2 pro-
moter. Furthermore, the effect was
specific because overexpression of
neither ELK1 nor SAP1a negative
dominant (SAP1aDBD) factors af-
fected the INSIG2 promoter trans-
activation (Fig. 7B).
Insulin Induces INSIG2 Promoter
Activation via SAP1a—Insulin reg-
ulates genes through two major sig-
naling pathways, namely the Ras-
MAPK cascade and the PI-3-kinase
pathway in hepatocytes (20, 21). In
view of the role of insulin in the
SREBP pathway and the role of
phosphorylated SAP1a in INSIG2
promoter activity through the Ras
pathway, we evaluated the effect of
insulin on the human INSIG2 pro-
moter activation and the role of
SAP1 in this effect. For this experi-
ment, we used primary rat hepato-
cytes because cell lines do not
respond properly to insulin. A
strong induction in luciferase activ-
ity was observed in rat hepatocytes
transiently transfected with a con-
struct containing the 347/11
INSIG2 promoter region after 24 h
of insulin treatment (Fig. 8). This
effect was not observed if the SAP1a
binding site was mutated, suggest-
ing that SAP1a is physiologically
important for INSIG2 gene regula-
tion by insulin in the hepatocytes.
There are two signals that contrib-
ute to lipogenic enzyme induction in
liver: glucose levels and insulin. We
also explored the contribution of glu-
cose to INSIG2 promoter activation.
As shown in Fig. 8, INSIG2 transacti-
vation was not affected by glucose
concentration.
A series of molecular and phys-
iologic alterations occurs in the
setting of insulin resistance that
results in the accumulation of tri-
glycerides in liver. SREBP1c regula-
tion of lipogenesis is highly involved
in the development of fatty livers in
animal models of insulin resistance
(22). However, taking into account
the insulin-dependent regulation
of SREBP1c, it might be antici-
pated that this isoform would not
Regulation of Human INSIG2 Gene Promoter
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be activated in states of insulin resistance. To explore the
relationship of the unexpected regulation of the human
INSIG2 gene by insulin with this paradox, we induced insulin
resistance in human hepatocytes. First of all, we verified that
a monolayer culture human hepatocytes only expressed the
INSIG2b variant (data not shown). As shown in Fig. 9, the
palmitic acid treatment induced insulin resistance in the
human hepatocytes as the decrease of GK expression
denotes. In this condition, there was a decrease in the levels
of INSIG2b with a subsequent increase in SREBP1c levels,
suggesting that INSIG2b regulation by insulin could play a
role in the regulation of SREBP1c expression in insulin
resistance states.
DISCUSSION
The present study has several major findings. First, we have
demonstrated that human liver or human cell lines only express
the INSIG2b variant. Second, we have characterized the mini-
mal human INSIG2 promoter located on the first 300 bp. Third,
we have identified an Ets binding site involved in the INSIG2
promoter activation. Finally, SAP1a is shown to be an essential
transcription factor that binds this human INSIG2 promoter
region. Moreover, phosphorylated SAP1a activates the human
INSIG2promoter and is one of themechanisms that controls its
insulin-dependent regulation.
Yabe et al. (9) identified a liver-specific mRNA for Insig2
from mouse liver, thereby suggesting its existence in humans
given the sequence homology between species. We therefore
sought to examine whether transcriptional regulation in
humans was also mediated through the use of different pro-
moters. The analysis of INSIG2mRNA expression in human
liver and in different human cell lines by RT-PCR showed
that the INSIG2b variant was the only mRNA form detected
in human samples (Fig. 1B). The oligonucleotides were
designed on the basis of conserved sequences of exons 1a and
1b between humans and mice (55 and 50% identical, respec-
tively) and the similar genome structure between humans
and rodents. However, we cannot exclude the possibility that
an exon 1a could be located in another region of the human
INSIG2 gene. To test this hypothesis, we are currently con-
ducting 5-rapid amplification of cDNA end analyses from
human liver RNA. To date, we have not yet found two differ-
ent 5 transcripts.
In this report, we have identified the core human INSIG2
promoter region. The human promoter is enclosed in a
300-bp region of DNA (Fig. 2). The analysis of potential sites
for regulation of this sequence allowed us to define the pres-
ence of at least one active binding site for proteins SAP1a and
ELK1 belonging to the TCF subfamily of Ets transcription
factors. The Ets gene family codes for transcription factors
that are involved in the generation of human cancers and in
cell transformation and development (23). Ets proteins con-
tain a conserved DNA binding region of about 85 amino
acids, called the Ets domain, that binds specifically to DNA
sequences with a core GGA element. This element is
involved in protein-protein interactions that are essential for
FIGURE5.ELK1andSAP1aproteinsbind to the INSIGpromoter.A, DNAsequence for human INSIG2proximal promoter. Thearrows indicate theprobesused
in the experiment. B, representative autoradiogram from a typical electrophoretic mobility shift assay realized with recombinant human proteins incubated
with 32P-probes. Anti-ELK1, anti-SAP1a, anti-NRF2a, or anti-E2F antibodies (Ab) were used for supershift assays, and competitions were carried out with a
25-fold molar excess of non-radiolabeled wild type (WT) or mutant (M) probes. C, ChIP assay was performed with HEK293T and HepG2 cells. Immunoprecipi-
tation of samples was performed with anti-ELK1, anti-SAP1a, or anti-SRF antibodies. A positive control of transcriptionally active genes was performed using
anti-RNA-polymerase II antibody, and a negative reaction was included using a nonspecific IgG antibody or in the absence of antibody. The relative -fold
enrichment of ELK1, SAP1a, or SRF binding sites is compared with the value of no antibody, which is set to 0. Representative quantitative PCRs of three
independent experiments are shown.
FIGURE 6. Knockdown experiments confirm that SAP1a regulates INSIG2
promoter activity. HepG2 cells were transfected with siRNA targeting ELK1
and SAP1a, and total mRNA was extracted. The level of knockdown was ana-
lyzed at the mRNA level using quantitative PCR for ELK1 or SAP1a (A). The
effect of RNA interference was evaluated by measuring endogenous INSIG2
and SREBP1 gene expression (B). All data were normalized to GAPDH expres-
sion. Theasterisks indicate a significant difference (*,p0.05) comparedwith
cells with the negative siRNA control used as calibrator. The knockdown
effect on ELK1 and SAP1a protein levels was analyzed by Western blot (C).
Nuclear extracts from HepG2 cells transfected with siRNA targeting ELK1 or
SAP1a were fractionated by SDS-PAGE, and immunoblots were developed
using anti-ELK1, anti-SAP1a, and anti-actin antibodies. A representative blot
of three experiments is shown. a.u., arbitrary units.
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biological activity (24). Ets mem-
bers are classical activators that
may play a primary role in forma-
tion of the initiation complex on
minimal core promoters lacking
the TATA sequence, such as thy-
midylate synthetase (25) or cyto-
chrome c oxidase subunit IV (26).
The human INSIG2 promoter may
be another gene where Ets pro-
teins could be a component of the
general transcription complex
around the start site.
SAP1a and ELK1 are expressed
at similar levels in the majority of
tissues (27), although SAP1a
seems to be more abundant than
ELK1 in liver. Accordingly, SAP1a
was found to be the exclusive Ets
factor that binds the INSIG2 pro-
moter in the hepatic cell line
HepG2, whereas both factors are
able to recognize Ets binding site
in HEK293T cells (Fig. 5C), indi-
cating that the cellular environ-
ment has a key role in dictating the
functional specificity of individual Ets domain proteins, as
shown by Boros et al. (28).
The TCF proteins form complexes with SRF dimers, as in
the c-fos gene promoter (29). However, SRF-independent
autonomous DNA binding of a TCF has been reported in the
absence of SRF. One example is the E74 gene in Drosophila,
which is activated by ELK1 and SAP1A in the absence of SRF
(30). Similarly, ELK1 and SAP1A regulate the mouse Cct
promoter (chaperon-containing t-complex polypeptide 1)
independently of SRF (31). The human INSIG2 promoter
would probably fall within this category of genes regulated
by TCF factors without SRF as a partner.
Boros et al. (28) provided insights into target gene selec-
tion by members of the Ets domain transcription factors,
highlighting redundancy of binding at some promoters but
highly selective function at others. The heterotypic interac-
tions with other transcription factors dictates this differen-
tial selection (28). Our data pointed to this latter event. As
shown in Fig. 2, a region between 347 and 152 bp must play
an important role in the control of the INSIG2 promoter
because its absence implies a 50% decrease in the activity of
the human promoter. To date, we have not been able to
identify proteins that might bind these sequences.
The Ets family of transcription factors is an effector of a
series of signaling pathways, including the MAPK kinase
pathways, ERK1/2, p38, and JNK, as well as the phospha-
tidylinositol 3-kinase pathway (32). ELK1 is poorly activated
by p38 MAPK, whereas SAP1a serves as a convergence point
for all three major classes of mammalian MAPK pathways.
Janjnecht et al. (33) demonstrated that SAP1a is phosphory-
lated by p38 MAPK, which efficiently activates c-fos tran-
scription in 293 cells. In this report, we have demonstrated
FIGURE 7. The phosphorylated form of SAP1a regulates the human promoter. A construct containing the
minimal human INSIG2 promoter region linked to a luciferase reporter plasmid was analyzed in HepG2 cells
cotransfected with pcDNA-ELK1 or pcDNA-SAP1a expression vectors and increasing amounts of expression
vector for a permanent active Ras protein (A) or pcDNA-SAP1a or SAP1a DBD (dominant negative form) in the
presence or absence of 50 ng/well K-Ras expression vector (B). After cell lysis, firefly and Renillla luciferase
activities were measured. Results represent relative firefly/Renilla luciferase activities. Values are the mean
S.E. from four separate experiments.
FIGURE 8. Insulin regulates human INSIG2 promoter activity. Wild type
347/11 INSIG2 promoter construct (INSIG2–300) or a mutated construct
where the SAP1a binding site is mutated by in vitro mutagenesis (mSAP1a)
was transfected into rat hepatocytes for 24 h. Cells were incubated inDulbec-
co’s modified Eagle’s medium containing low (1 g/liter) or high (4.5 g/liter)
glucose in the absence (basal) or presence of 100 nM insulin (Ins). After 24 h,
the cells were lysed for luciferase assays. The relative firefly/Renilla luciferase
activities of the constructs as well as their response to glucose or insulin were
comparedwith theactivityof thewild-typeconstructwith lowglucose,which
was set to 1 S.E. Values are themean S.E. from four separate experiments.
The asterisks indicate significant difference (*, p 0.05), as determined using
Student’s t test.
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that INSIG2 promoter transactivation by SAP1a is depen-
dent on its phosphorylation status and is achieved by activa-
tion of the Ras protein. This is particularly important
because the Ras-MAPK route, especially ERK1/2, is one of
the cascades involved in regulating the metabolic response
to insulin (34). Although TCFs historically regulate genes of
immediate response, some literature reports describe the
hormonal or nutritional regulation exerted by some of these
factors. In 3T3-F442A preadipocytes, for example, ELK1 and
SAP1A proteins mediate the induction of Egr1 transcription
caused by growth hormone in an SRF-dependent manner
(35, 36). It has also been shown that the ternary complex
between ELK1 and SRF binds to two active sites in the
human LXR promoter to regulate the glucose-dependent
response of LXR gene expression (37). Furthermore, ELK1
and SAP1a specifically bind to insulin response elements in
the prolactin, somatostatin, and thymidine kinase genes,
independently of SRF binding (38). Our data suggest that
SAP1a could be involved in both human INSIG2 basal activ-
ity and also in some other type of metabolic regulation. We
are therefore currently preparing transgenic mice that
express luciferase gene reporter under the wild-type human
promoter and the promoter mutated on the ELK1/SAP1a
binding site. If the above hypothesis is correct, we should be
able to observe a different luciferase gene expression under
fasting/refeeding conditions.
INSIG genes were initially identified as the most abundant
insulin-induced genes in a hepatic cell line (39); therefore, it
is not surprising that our data show a positive regulation of
human INSIG2 gene expression by insulin. However, the
current findings do not explain the paradox whereby insulin
induces the expression of SREBP1c and its negative regula-
tors INSIG1 and INSIG2 simultaneously. Yellaturu et al. (40)
have recently proposed that the stimulation of SREBP1c
processing by insulin is mediated by a selective depletion of the
INSIG2a protein by promoting decay of its cognate mRNA. It
might be anticipated that SREBP1c would not be activated in
states of insulin resistance. However, even in the presence of
profound insulin resistance, the
hepatic SREBP1c transcription is
stimulated (41). Our data (Fig. 9)
show that INSIG2b regulation by
insulin could play an important role
in explaining this paradox.
We could not definitely rule out
the possibility that human liver
presents an INSIG2mRNA variant
equivalent to Insig2a present in
the liver of rodents. However, our
data raise a question regarding the
regulation of hepatic SREBP1c
processing in response to insulin
and provide the base for further
research to develop a full under-
standing of additional signal trans-
duction pathways that control the
expression of INSIG2.
In conclusion, we have cloned
and characterized the proximal human INSIG2 promoter.
Our data demonstrate for the first time that members of the
Ets family of transcription factors are involved in the regu-
lation of human INSIG2 expression and therefore of SREBP
processing. Using deletion constructions and siRNA knock-
down analysis, we have identified one functional SAP1a
binding site that controls basal promoter activity. Moreover,
insulin activates the human INSIG2 promoter in a process
that is probably mediated by phosphorylated SAP1a, thereby
suggesting an unexpected mechanism of INSIG2 gene
expression regulation. Our findings provide a basis for the
characterization of signal transduction pathways that con-
trol the expression of human INSIG2 in the liver.
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